Keio University

Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai

Other

Terumo Kabushiki Kaisha

Kazuo Umezawa

Tomio Takeuchi

Shinichi Kondo

Hiroaki Takahashi

Takashi Yoshida

Sumio Umezawa

Masa Hamada

Takeo Yoshioka

Tsutomu Tsuchiya

Yoshiaki Takahashi

Hiroshi Naganawa

Daishiro Ikeda

Yoshihiko Kobayashi

Yasushi Takagi

Shigeru Nishiyama

Kunio Isshiki

Tsutomu Sawa

Yoshiyuki Koyama

Yoko Ikeda

Naoki Matsumoto

Tetsuo Shitara

Naoki Agata

Shin-ichi Hirano

Itaru Kojima

Yuichi Ishikawa

Ayumi Kaneda

Sakino To-E

Miyuki Tachibana

Mikio Fujii

Takashi Koyano

Keiichi Ajito

Sonoko Hirose

Hisako Ohgawara

The object of the present invention is to provide a pharmaceutical composition that inhibits expression of iNOS and COX-2 without inhibiting NF-&#x3ba;B. The pharmaceutical composition that inhibits expression of iNOS and COX-2 without inhibiting NF-&#x3ba;B contains DTCM glutarimide of the Formula (I) as an effective ingredient, thereby being able to inhibit nitric oxide (NO) production and prostaglandin production.

Pharmaceutical compositions

An agent containing a vinca alkaloid or its pharmacologically acceptable salt as an active ingredient can induce insulin production and/or secretion of non-neoplastic cells derived from the pancreas.

Use of vinca alkaloids and salts thereof

PROBLEMS TO BE SOLVED BY THE INVENTION To provide aqueous solutions of conophylline and/or conophyllidine; methods for purifying conophylline and/or conophyllidine from the aqueous solutions; methods for producing the aqueous solutions, water-soluble compositions containing conophylline and/or a conophyllidine useful for food compositions or pharmaceutical compositions or methods for preparing the same; as well as food compositions or pharmaceutical compositions containing the water-soluble compositions. MEANS OF SOLVING THE PROBLEMS It has been found that conophylline and/or conophyllidine can be efficiently extracted from a plant producing conophylline and/or conophyllidine with an acidic aqueous solution having a pH equal to or less than 4. The extract thus obtained, i.e., aqueous solution of conophylline, and/or conophyllidine is useful for production of, for instance, food compositions, pharmaceutical compositions, etc.

Aqueous solution of conophylline and/or conophyllidine

Salicylamide derivatives represented by formulae ( ) and ( ); intermediates in the production thereof; a process for producing the same; and drugs containing the same as the active ingredient. The salicylamide derivatives represented by formulae ( ) and ( ) are useful as anti-inflammatory agents and immunosuppressive agents which exert an effect of inhibiting the activation of NF-&kgr;B with little side effects.

Salicylamide derivatives

As novel substances having an activity of inducing an apoptosis even on the apoptosis-resistant cancer cells, there are obtained polyoxypeptin and deoxypolyoxypeptin represented by the following general formula (I)

Physiologically active polyoxypeptin and deoxypolyoxypeptin and anticancer drugs containing the same

A compound isolated from Ervatamia microphylla has been found to be effective in inducing a change in cell morphology and growth habits of cultured transformant cell lines, and in reducing the tumor size in a living mammal. The compound is capable of inhibiting the function of oncogenes such as ras and src by inhibiting the function of the oncogene products. The compound is found to be represented by formula (I): ##STR1## Use of the compound as an oncogene function inhibitor, in a treatment of cancer, and in inducing changes in cell morphology and growth habits in transformant cell line are contemplated.

Oncogene function-inhibitory agent, method for inhibiting oncogene

As new compounds are now provided 14-O-(3,4-disubstituted benzoyl)adriamycins which are of low cytotoxicity and exhibit a high activity inhibitory to the reverse transcriptase of human immunodeficiency virus (HIV) and which can inhibit propagation of HIV.

Anthracycline derivatives having inhibitory activity against reverse

As new compound are now provided ten compounds, namely 1-N-{(2R,3R)-4-amino-3-fluoro-2-hydroxybutyryl}kanamycin A; 1-N-{(2R,3R)-4-amino-3-fluoro-2-hydroxybutyryl}-2',3'-dideoxykanamycin A; 1-N-{(2R,3R)-4-amino-3-fluoro-2-hydroxybutyryl}-2',3'-dideoxy-2'-fluorokan amycin A; 1-N-{(2R,3R)-4-amino-3-fluoro-2-hydroxybutyryl}-5-deoxy-5-fluorokanamycin A; 1-N-{(2R,3R)-4-amino-3-fluoro-2-hydroxybutyryl}-kanamycin B; 1-N-{(2R,3R)-4-amino-3-fluoro-2-hydroxybutyryl}-3'-deoxykanamycin B; 1-N-{(2R,3R)-4-amino-3-fluoro-2-hydroxybutyryl}-3',4'-dideoxykanamycin B; 1-N-{(2R,3R) -4-amino-3-fluoro-2-hydroxybutyryl}-5-deoxy-5-fluorokanamycin B; 1-N-{(2R,3R)-4-amino-3-fluoro-2-hydroxybutyryl}-5,3'-dideoxy-5-fluorokanam ycin B; and 1-N{(2R,3R)-4-amino-3-fluoro-2-hydroxybutyryl}-5,3',4'-trideoxy-5-fluoroka namycin B, which are all useful as antibacterial agent in the therapeutic treatment of bacterial infections.

1-n-(4-amino-3-fluoro-2-hydroxybutyryl)-kanamycins

Growing community of inventors

Kanagawa, Japan

Kazuo Umezawa